



## Conversion of Guanosine into Isoguanosine and Derivatives

K. J. Divakar, Mina Mottahedeh, Colin B. Reese,\* Yogesh S. Sanghvi and Karl A. D. Swift  
 Department of Chemistry, King's College London, Strand, London WC2R 2LS, UK

Treatment of 2-amino-6-chloro-9-(2,3,5-tri-*O*-acetyl- $\beta$ -D-ribofuranosyl)purine **7**, which is readily prepared from guanosine **2** in two steps, with toluene-4-thiol and triethylamine followed by sodium nitrite in aqueous acetic acid gives 6-[(4-methylphenyl)thio]-2-oxo-9-(2,3,5-tri-*O*-acetyl- $\beta$ -D-ribofuranosyl)-2,3-dihydropurine **9**. When the latter compound (**9**) is treated with ammonia in aqueous ethanol at 70 °C, methylamine in industrial methylated spirit at room temperature, dimethylamine in industrial methylated spirit at 50 °C, and aniline, under reflux, in pyridine solution followed by methanolic ammonia at room temperature, isoguanosine **1**, 6-*N*-methylisoguanosine **12a**, 6,6-di-*N*-methylisoguanosine **12b**, and 6-*N*-phenylisoguanosine **12c**, respectively, are obtained in satisfactory yields.

Isoguanosine **1**, which is sometimes referred to as crotonoside or 2-hydroxyadenosine, is a naturally occurring, biologically active isomer of guanosine **2**; it was first isolated<sup>1</sup> in 1932 from *Croton tiglium* L. Isoguanosine is incorporated into mammalian but not into bacterial nucleic acids,<sup>2</sup> and is reported to stimulate the accumulation of cyclic-AMP in the brain;<sup>3</sup> it is an inhibitor of IMP pyrophosphorylase,<sup>4</sup> and its 5'-di- and -tri-phosphates inhibit glutamic acid dehydrogenase.<sup>5</sup>

phenyl derivatives. Our procedure is related to a previously reported method<sup>10</sup> involving 6-chloro-2-iodo-9-( $\beta$ -D-ribofuranosyl)purine **6** as an intermediate, and involves the same number of steps; however, unlike the latter method, it avoids a relatively low yielding and possibly scale-limiting photochemical step and leads to an intermediate which is a common precursor both of isoguanosine **1** and its 6-*N*-alkyl and -aryl derivatives (see below).



**Scheme 1** Reagents and conditions: i, toluene-4-thiol, triethylamine, DMF, 100 °C, 1 h; ii, NaNO<sub>2</sub>, acetic acid-water (1:1 v/v), 50 °C, 1 h

Several methods for the synthesis of isoguanosine **1** have been reported in the literature; some of the methods are based<sup>6,7</sup> on the relatively inaccessible 5-amino-1-( $\beta$ -D-ribofuranosyl)imidazole-4-carboxamide **3** as starting material and some involve the modification of other 9-( $\beta$ -D-ribofuranosyl)purines, such as 2-aminoadenosine<sup>8</sup> **4** or adenosine 1-oxide<sup>9</sup> **5**. We now report a very convenient procedure for the conversion of guanosine **2**, a relatively cheap starting material, into isoguanosine **1** and its 6-*N*-methyl, 6,6-di-*N*-methyl and 6-*N*-

2-Amino-6-chloro-9-(2,3,5-tri-*O*-acetyl- $\beta$ -D-ribofuranosyl)purine **7** was prepared from guanosine **2** in 71% overall yield, using Robins and Uznanski's chlorination procedure.<sup>11</sup> When compound **7** was heated (see Scheme 1) with *ca.* 2.0 mol equiv. of toluene-4-thiol and 1.0 mol equiv. of triethylamine in anhydrous dimethylformamide (DMF) at 100 °C for 1 h, 2-amino-6-[(4-methylphenyl)thio]-9-(2,3,5-tri-*O*-acetyl- $\beta$ -D-ribofuranosyl)purine **8** was obtained as a crystalline solid in 92% isolated yield. Treatment of compound **8** with a very large excess of sodium nitrite in aqueous acetic acid at 50 °C gave 6-[(4-methylphenyl)thio]-2-oxo-9-(2,3,5-tri-*O*-acetyl- $\beta$ -D-ribofuranosyl)-2,3-dihydropurine **9** which was isolated as a glassy material in almost quantitative yield. The latter compound is the key intermediate



(2 H, d, *J* 8.0), 7.49 (2 H, d, *J* 8.0) and 8.39 (1 H, s);  $\delta_{\text{C}}[(\text{CD}_3)_2\text{SO}]$  20.12, 20.29, 20.42, 20.79, 62.84, 70.09, 71.86, 79.61, 85.13, 123.18, 125.71, 129.98, 135.12, 139.24, 141.51, 151.04, 160.61, 169.22, 169.37 and 170.03.

**2',3'-O-Isopropylidene-6-[(4-methylphenyl)thio]-2-oxo-9-( $\beta$ -D-ribofuranosyl)-2,3-dihydropurine 10.**—Methanolic sodium methoxide (ca. 4.4 mol dm<sup>-3</sup>; 8.8 cm<sup>3</sup>, ca. 38.5 mmol) was added to a stirred solution of compound **9** (5.19 g, ca. 10.1 mmol) in methanol (40.2 cm<sup>3</sup>) at room temperature. After 15 min, the products were neutralized by the addition of Dowex 50  $\times$  8 (H<sup>+</sup>-form) cation-exchange resin. The mixture was then filtered and the residue was washed with ethanol several times. The combined filtrate and washings were concentrated under reduced pressure. The residual glass was dissolved in the minimum quantity of chloroform-ethanol (1:1 v/v), and the resulting solution was added dropwise to light petroleum. The white solid [2.99 g, *R<sub>f</sub>* 0.34 (system A)] thus obtained was collected by centrifugation, washed with light petroleum and dried.

2,2-Dimethoxypropane (10.16 cm<sup>3</sup>, 82.6 mmol) was added to a stirred solution of the above product (2.99 g) and PTSA monohydrate (1.80 g, 9.5 mmol) in anhydrous DMF (19 cm<sup>3</sup>) at room temperature. After 2 h, the products were neutralized (pH paper) with methanolic ammonia (half-saturated at 0 °C), and then concentrated under reduced pressure. The residue obtained was fractionated by short-column chromatography on silica gel: the appropriate fractions, eluted with chloroform-ethanol (95:5 v/v), were combined, and evaporated under reduced pressure to give a glass (2.31 g, ca. 53% overall yield for the two steps); *R<sub>f</sub>* 0.53 (system A);  $\delta_{\text{H}}(\text{CDCl}_3)$  1.36 (3 H, s), 1.62 (3 H, s), 2.16 (3 H, s), 3.79 (1 H, dd, *J* 2.3 and 12.7), 3.97 (1 H, dd, *J* 1.8 and 12.7), 4.47 (1 H, m), 5.10 (1 H, dd, *J* 1.4 and 6.0), 5.21 (1 H, dd, *J* 4.7 and 5.9), 5.79 (1 H, d, *J* 4.6), 7.14 (2 H, d, *J* 7.9), 7.46 (2 H, d, *J* 8.1) and 7.86 (1 H, s);  $\delta_{\text{C}}(\text{CDCl}_3)$  21.13, 25.24, 27.54, 63.18, 81.54, 82.70, 86.32, 93.28, 114.09, 119.54, 123.45, 131.04, 135.34, 141.73, 142.97, 153.19, 156.82 and 157.25.

**2',3'-O-Isopropylideneisoguanosine 11.**—Conc. aq. ammonia (*d* 0.88; 1.09 cm<sup>3</sup>) was added to a solution of 2',3'-O-isopropylidene-6-[(4-methylphenyl)thio]-2-oxo-9-( $\beta$ -D-ribofuranosyl)-2,3-dihydropurine **10** (0.30 g, ca. 0.70 mmol) in 1,4-dioxane (7 cm<sup>3</sup>) and the reactants were heated at 70 °C in Pierce Reacti-Vials for 6 h. The product was then cooled, and concentrated under reduced pressure. After the residue had been triturated with diethyl ether, it was crystallized from absolute ethanol to give 2',3'-O-isopropylideneisoguanosine **11** (0.17 g, ca. 75%) as crystals, m.p. 280 °C, identical [<sup>1</sup>H and <sup>13</sup>C NMR, UV, TLC (system A)] with material prepared<sup>12</sup> by another route.

**Isoguanosine 1.**—(a) A stirred solution of 2',3'-O-isopropylideneisoguanosine **11** (0.50 g, 1.55 mmol) in formic acid-water (4:1, v/v; 5 cm<sup>3</sup>) was kept at room temperature for 4 h. The products were then concentrated under reduced pressure and the residue was co-evaporated three times with absolute ethanol. Crystallization of the resultant material from water gave the title compound **1** (0.39 g, 86%) (Found, in material dried *in vacuo* at 100 °C: C, 41.0; H, 4.75; N, 23.5. Calc. for C<sub>10</sub>H<sub>13</sub>N<sub>5</sub>O<sub>5</sub>·0.6H<sub>2</sub>O: C, 40.8; H, 4.9; N, 23.8%), m.p. 236–238 °C (decomp.) (lit.<sup>9,10</sup> 237–241 °C);  $\lambda_{\text{max}}(\text{water})/\text{nm}$  292 ( $\epsilon$  11 000) and 247 (8800);  $\lambda_{\text{min}}/\text{nm}$  264 ( $\epsilon$  2900) and 229 (4200); *R<sub>f</sub>* 0.58 (system B); *t<sub>R</sub>*[water-methanol (95:5 v/v)] 7.0 min;  $\delta_{\text{H}}[(\text{CD}_3)_2\text{SO}-\text{D}_2\text{O}]$  3.56 (1 H, dd, *J* 2.8 and 12.3), 3.66 (1 H, dd, *J* 2.8 and 12.3), 3.98 (1 H, m), 4.11 (1 H, dd, *J* 2.7 and 4.9), 4.50 (1 H, m), 5.67 (1 H, d, *J* 6.4) and 7.97 (1 H, s);  $\delta_{\text{C}}[(\text{CD}_3)_2\text{SO}]$  61.63, 70.71, 72.98, 85.94, 87.69, 109.67, 138.07, 152.59, 156.03 and 160.61.

(b) Conc. aq. ammonia (*d* 0.88; 9 cm<sup>3</sup>) was added

to a solution of 6-[(4-methylphenyl)thio]-2-oxo-9-(2,3,5-tri-*O*-acetyl- $\beta$ -D-ribofuranosyl)-2,3-dihydropurine **9** (0.35 g, ca. 0.68 mmol) in ethanol (3 cm<sup>3</sup>). The resulting solution was heated at 70 °C in Pierce Reacti-Vials for 17 h. The products were then concentrated under reduced pressure and ethanol (5 cm<sup>3</sup>) was added. The resulting mixture was re-evaporated under reduced pressure, and this process was repeated twice more. The residue was triturated several times with diethyl ether and was then dissolved in a hot mixture of ethanol (12.5 cm<sup>3</sup>) and water (12.5 cm<sup>3</sup>). The resulting solution was heated with activated charcoal, under reflux, for ca. 5 min, and was then cooled, and filtered through Celite. Concentration of the filtrate gave isoguanosine **1** (0.141 g, ca. 73%) as a solid. After recrystallization from methanol, the product was identical [m.p., <sup>1</sup>H and <sup>13</sup>C NMR, LC] with the material obtained in section (a) above.

**6-N-Methylisoguanosine 12a.**—6-[(4-Methylphenyl)thio]-2-oxo-9-(2,3,5-tri-*O*-acetyl- $\beta$ -D-ribofuranosyl)-2,3-dihydropurine **9** (1.00 g, ca. 1.94 mmol) was dissolved in a 33% solution of methylamine in industrial methylated spirit (14 cm<sup>3</sup>; ca. 0.116 mol of methylamine), and the resulting solution was stirred at room temperature for 3 h. The products were then concentrated under reduced pressure and the residue was triturated several times with diethyl ether. The residual solid was crystallized from ethanol to give the title compound **12a** (0.52 g, ca. 90%) (Found, in material dried *in vacuo* at 80 °C: C, 41.7; H, 5.1; N, 22.0. Calc. for C<sub>11</sub>H<sub>15</sub>N<sub>5</sub>O<sub>5</sub>·H<sub>2</sub>O: C, 41.9; H, 5.4; N, 22.2%); m.p. 188–190 °C;  $\lambda_{\text{max}}(95\% \text{ EtOH})/\text{nm}$  281 ( $\epsilon$  7600) and 247 (8600);  $\lambda_{\text{inf}}/\text{nm}$  300 ( $\epsilon$  5800);  $\lambda_{\text{min}}/\text{nm}$  265 ( $\epsilon$  5800) and 237 (6700); *R<sub>f</sub>* 0.58 (system B); *t<sub>R</sub>*[water-methanol (95:5 v/v)] 14.3 min;  $\delta_{\text{H}}[(\text{CD}_3)_2\text{SO}]$  2.95 (3 H, br s), 3.62 (2 H, m), 3.98 (1 H, m), 4.12 (1 H, m), 4.50 (1 H, m), 5.20 (1 H, br), 5.47 (1 H, br), 5.71 (1 H, d, *J* 6.3) and 7.94 (1 H, s);  $\delta_{\text{C}}[(\text{CD}_3)_2\text{SO}]$  38.13, 61.48, 70.54, 73.27, 85.60, 87.45, 113.77, 136.18, 151.17, 154.13 and 158.65.

**6,6-Di-N-Methylisoguanosine 12b.**—6-[(4-Methylphenyl)thio]-2-oxo-9-(2,3,5-tri-*O*-acetyl- $\beta$ -D-ribofuranosyl)-2,3-dihydropurine **9** (1.00 g, ca. 1.94 mmol) was dissolved in a 33% solution of dimethylamine in industrial methylated spirit (14 cm<sup>3</sup>, ca. 78 mmol of dimethylamine), and the resulting solution was heated at 50 °C for 3 h. The products were then concentrated under reduced pressure and the residue was triturated several times with diethyl ether. The residual solid was crystallized from methanol to give the title compound (0.57 g, ca. 93%) (Found, in material dried *in vacuo* at 80 °C: C, 46.0; H, 5.6; N, 22.0. Calc. for C<sub>12</sub>H<sub>17</sub>N<sub>5</sub>O<sub>5</sub>·0.2H<sub>2</sub>O: C, 45.8; H, 5.6; N, 22.2%); m.p. 230–232 °C (decomp.);  $\lambda_{\text{max}}(95\% \text{ EtOH})/\text{nm}$  278 ( $\epsilon$  10 800) and 253 (11 500);  $\lambda_{\text{inf}}/\text{nm}$  306 ( $\epsilon$  4400);  $\lambda_{\text{min}}/\text{nm}$  266 ( $\epsilon$  8300) and 241 ( $\epsilon$  9300); *R<sub>f</sub>* 0.72 (system B); *t<sub>R</sub>*[water-ethanol (85:15 v/v)] 8.7 min;  $\delta_{\text{H}}[(\text{CD}_3)_2\text{SO}]$  3.41 (6 H, br s), 3.54 (1 H, dd, *J* 3.2 and 12.1), 3.65 (1 H, dd, *J* 3.2 and 12.0), 3.93 (1 H, m), 4.10 (1 H, m), 5.14 (1 H, d, *J* 4.2), 5.40 (2 H, m), 5.76 (1 H, d, *J* 6.2) and 8.03 (1 H, s);  $\delta_{\text{C}}[(\text{CD}_3)_2\text{SO}]$  38.07, 61.48, 70.52, 73.27, 85.59, 87.45, 113.84, 136.11, 151.27, 154.27 and 159.01.

**6-N-Phenylisoguanosine 12c.**—6-[(4-Methylphenyl)thio]-2-oxo-9-(2,3,5-tri-*O*-acetyl- $\beta$ -D-ribofuranosyl)-2,3-dihydropurine **9** (1.00 g, ca. 1.94 mmol) and freshly distilled aniline (0.36 cm<sup>3</sup>, 3.95 mmol) were heated together, under reflux, in anhydrous pyridine (24 cm<sup>3</sup>) solution under nitrogen, for 53 h. The products were then concentrated under reduced pressure, and the residue was fractionated by short-column chromatography on silica gel to give a light-purple coloured glass (0.64 g); *R<sub>f</sub>* 0.63 (system A). A portion of this material (0.20 g) was dissolved in methanolic ammonia (half-saturated at 0 °C). After the solution had been kept at room temperature for 15 h, it was concentrated under reduced pressure and the residue was triturated several times with diethyl ether. Crystallization of the solid residue from

water gave the *title compound 12c* (0.14 g, ca. 61% overall yield) (Found: C, 50.5; H, 5.0; N, 18.4.  $C_{16}H_{17}N_5O_5 \cdot H_2O$  requires C, 50.9; H, 5.1; N, 18.6%); m.p. 156–158 °C;  $\lambda_{max}(95\% \text{ EtOH})/nm$  301 ( $\epsilon$  22 900) and 240 (7900);  $\lambda_{min}/nm$  265 ( $\epsilon$  5800) and 237 (6700);  $R_f$  0.09 (system A), 0.60 (system B);  $\delta_H[(CD_3)_2SO]$  3.58 (1 H, dd,  $J$  3.2, 12.1), 3.69 (1 H, dd,  $J$  3.3, 12.0), 3.97 (1 H, m), 4.14 (1 H, m), 4.51 (1 H, m), 5.20 (1 H, br), 5.48 (1 H, br), 5.82 (1 H, d,  $J$  6.3), 7.03 (1 H, t,  $J$  7.3), 7.31 (2 H, m), 7.96 (2 H, d,  $J$  7.7), 8.19 (1 H, s) and 9.79 (1 H, br);  $\delta_C[(CD_3)_2SO]$  61.44, 70.55, 73.39, 85.66, 87.45, 114.97, 120.86, 122.66, 128.30, 137.77, 139.39, 153.07 and 159.71.

### Acknowledgements

We thank the Cancer Research Campaign for generous financial support; one of us (M. M.) thanks the SERC for the award of a research studentship.

### References

- 1 E. Cherbuliez and K. Bernhard, *Helv. Chim. Acta*, 1932, **15**, 464, 978.
- 2 B. A. Lowy, J. Davoll and G. B. Brown, *J. Biol. Chem.*, 1952, **197**, 591; M. E. Balis, D. H. Levin, G. B. Brown, G. B. Elion, H. Vanderwerff and G. H. Hitchings, *J. Biol. Chem.*, 1952, **199**, 227.
- 3 M. Huang, H. Shimizu and J. W. Daly, *J. Med. Chem.*, 1972, **15**, 462.
- 4 C. Hagen, *Biochim. Biophys. Acta*, 1973, **293**, 105.
- 5 H. H. Montsch, I. Goia, M. Kezdi, O. Barzu, M. Dansoreanu, G. Jebeleanu and N. G. Ty, *Biochemistry*, 1975, **14**, 5593.
- 6 A. Yamazaki, I. Kumashiro, T. Takenishi and M. Ikehara, *Chem. Pharm. Bull.*, 1968, **16**, 2172.
- 7 J.-Y. Chern, H.-Y. Lee, M. Huan and F.-Y. Shish, *Tetrahedron Lett.*, 1987, **28**, 2151.
- 8 J. Davoll, *J. Am. Chem. Soc.*, 1951, **73**, 3174.
- 9 F. Cramer and G. Schlingloff, *Tetrahedron Lett.*, 1964, 3201.
- 10 V. Nair and D. A. Young, *J. Org. Chem.*, 1985, **50**, 406.
- 11 M. J. Robins and B. Uznanski in *Nucleic Acid Chemistry, Improved and New Synthetic Procedures, Methods, and Techniques, Part 3*, eds. L. B. Townsend and R. S. Tipson, Wiley-Interscience, New York, 1986, pp. 144 *et seq.*
- 12 C. B. Reese, Y. S. Sanghvi and R. Kuroda, *J. Chem. Soc., Perkin Trans. 1*, 1987, 1527.
- 13 K. J. Divakar and C. B. Reese, *J. Chem. Soc., Chem. Commun.*, 1980, 1191.
- 14 I. M. Buck and C. B. Reese, *J. Chem. Soc., Perkin Trans. 1*, 1990, 2937.

Paper 0/047581

Received 23rd October 1990

Accepted 14th November 1990